TEVA-ATENOLOL 50 MG
ATENOLOL : 50 MG · DIN 01912062 · TEVA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is TEVA-ATENOLOL?
TEVA-ATENOLOL 50 MG contains ATENOLOL : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 01912062, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 24-Jul-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-ATENOLOL used for?
TEVA-ATENOLOL (atenolol) tablets are indicated in patients with mild or moderate hypertension. It is usually used in combination with other drugs, particularly a thiazide diuretic. TEVA-ATENOLOL tablets are also indicated in the long-term management of patients with angina pectoris due to ischemic heart disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01912062 |
|---|---|
| Brand name | TEVA-ATENOLOL |
| Generic / active ingredient | ATENOLOL : 50 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C07AB03 ATENOLOL |
| AHFS class | 24:24.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 24-Jul-2015 |
| Original market date | 1991-12-31 00:00:00 |
How is it administered?
Hypertension: Initial 50 mg once daily, may increase to 100 mg. Angina: Initial 50 mg once daily, may increase to 100 mg once daily or 50 mg twice daily. Adjust for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15 - 30°C. Store at room temperature protected from light and moisture.
How is it supplied?
25 mg tablets - Supplied in bottles of 100. 50 mg tablets - Supplied in bottles of 100 and 500, in patient pack of 30, and in unit dose strips of 100. 100 mg tablets - Supplied in bottles of 100 and 500, in patient pack of 30, and in unit dose strips of 100.
Contraindications
Sinus bradycardia, A-V block (2nd/3rd degree), sick sinus syndrome, heart failure, cardiogenic shock, hypotension, severe peripheral arterial disorders, metabolic acidosis, hypersensitivity.
Warnings and precautions
Avoid abrupt cessation (risk of MI/arrhythmia). Caution in cardiac failure, Prinzmetal's angina, sinus bradycardia, thyrotoxicosis, and bronchospastic disorders.
Is ATENOLOL in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C07AB03 ATENOLOL. 28 of 87 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-ATENOL TAB 100MG | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 00773697 |
| APO-ATENOL TAB 50MG | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 00773689 |
| ATENOLOL | 100 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00828793 |
| ATENOLOL | 100 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02238318 |
| ATENOLOL | 25 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02326701 |
| ATENOLOL | 25 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02541564 |
| ATENOLOL | 50 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02238316 |
| ATENOLOL | 50 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00828807 |
| JAMP-ATENOLOL | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02367572 |
| JAMP-ATENOLOL | 25 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02367556 |
Who else supplies ATENOLOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ATENOLOL appears in 359 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.